Do you want to read an article? Please log in or register.
JAK inhibitors safety in ulcerative colitis: practical implications
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy
J Crohns Colitis.
Panés J, Lindsay JO, Teich N, Lindgren S, Colombel JF, Cornillie F, Flynn HA, Huyck S, Stryszak P, Yao R, Philip G, Reinisch W
doi: 10.1093/ecco-jcc/jjz048.
Inflammatory Bowel Disease
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
Eur J Gastroenterol Hepatol.
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D
doi: 10.1097/MEG.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Am J Gastroenterol.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S
doi: 10.14309/ajg.0000000000000596.
Inflammatory Bowel Disease
The safety of beclomethasone dipropionate in the treatment of ulcerative colitis
Expert Opin Drug Saf.
Rizzello F, Mazza M, Salice M, Calabrese C, Calafiore A, Campieri M, Gionchetti P
doi: 10.1080/14740338.
Inflammatory Bowel Disease
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
Clin Gastroenterol Hepatol
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE
doi: 10.1016/j.cgh.2021.02.043
Inflammatory Bowel Disease
Current Practices in Ileal Pouch Surveillance for Patients with Ulcerative Colitis: A Multinational, Retrospective Cohort Study
J Crohns Colitis.
Samaan MA, Forsyth K, Segal JP, de Jong D, Vleugels J, Elkady S, Kabir M, Campbell S, Kok K, Armstrong DG, Penez L, Arenaza AP, Seward E, Vega R, Mehta S, Rahman F, McCartney S, Bloom S, Patel K, Pollok R, Westcott E, Darakhshan A, Williams A, Koumoutsos I, Ray S, Mawdsley J, Anderson S, Sanderson JD, Dekker E, D'Haens GR, Hart A, Irving PM
doi: 10.1093/ecco-jcc/
RECOMMENDED
Inflammatory Bowel Disease
DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflammation) score, a simple method to quantify inflammatory burden in Ulcerative Colitis
J Crohns Colitis.
Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan EJ,
Doherty GA
doi: 10.1093/ecco-jcc/jjz067.
ECCO 2019
Inflammatory Bowel Disease
Ulcerative colitis
Lair-Mehiri L et al. 2019. Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Poster presentation at: ECCO 2019 Congress; 6–9 March; Copenhagen, Denmark.